Table 2.
Characteristics of Vi-Pfs25 conjugates.
| Conjugate-Lot# | Modification | Modification ADH% (wt%) | Conjugation Input ratio (Pfs25: Vi) | Final conjugate composition: Pfs25/Vi (w/w) | Average Conjugate Size (Mw) |
|---|---|---|---|---|---|
| ViADH-Pfs25–21 | Low-ADH (Method 1) | 4.0 | 1.3: 1 | 1.13 | 3.8 mDa |
| ViADH-Pfs25–22 (ViLowADH-Pfs25)* | Low-ADH (Method 1) | 4.5 | 1.2: 1 | 0.82 | 4.1 mDa |
| ViADH-Pfs25–23 | High-ADH (Method 1) | 18.9 | 1.2: 1 | 1.27 | 5.2 mDa |
| ViADH-Pfs25–24 (ViHighADH-Pfs25)* | High-ADH (Method 1) | 25.9 | 1.2: 1 | 0.92 | 5.0 mDa |
| Vi-Pfs25ADH-25 (Vi-Pfs25ADH)* | Modified Pfs25 (Method 2) | 3.8 | 2.0:1 | 0.53 | 0.37 mDa |
*
These conjugates were evaluated in mouse immunogenicity studies and are referred to by these labels in the text and figures describing the results from the immunogenicity studies.